Mammakarzinom

Ahr A, Kahn T, Solbach C, Seiter T, Strelhardt K, Holtrich H, Kaufmann M (2002) Identification of high risk breast cancer patients by gene expression profiling. Lancet 359: 131–133PubMedCrossRefGoogle Scholar

Albain KS, Nag S, Calderillo-Ruiz G, Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 22, 14S (Abstr 510)Google Scholar

Batson OV (1967) The vertebral system of veins as a means for cancer dissemination. Prog Clin Cancer 3: 1–18PubMedGoogle Scholar

Bear HD, Anderson S, Smith RE et al. (2004) A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed bei preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat 88: 16 (Abstr)Google Scholar

Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases. Lancet II(104): 162CrossRefGoogle Scholar

Biganzoli B, Cufer T, Bruning P et al. (2000) Doxorubicin (A)/taxol (T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. Proc ASCO 19: 282Google Scholar

Black MM, Speer FD (1957) Nuclear structure in cancer tissues. Surg Gynecol Obstet 105: 97–105PubMedGoogle Scholar

Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1049 cases, of which 359 have been followed 15 years. Br J Cancer 11: 359–377PubMedGoogle Scholar

Bloomfield DJ (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16(3): 1218–1225PubMedGoogle Scholar

Bonadonna G, Brusamolino E, Valagussa P et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J med 294: 405–410PubMedCrossRefGoogle Scholar

Bonadonna G, Valagussa P, Moliterni A et al. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positiv breast cancer: the results of 20 years of follow-up (see comments). N Engl J Med 332: 901–906PubMedCrossRefGoogle Scholar

Bonneterre J, Thurlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22): 3748–3757PubMedGoogle Scholar

Bonneterre J, Roche H, Kerbrat P et al. (2004) Long-term cardiac follow-up in relapse free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as ad juvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 22: 3070–3079PubMedCrossRefGoogle Scholar

Boyd NF, Martin LJ, Noffel M, Lockwood GA, Trichler DL (1993) A meta-analysis of studies of dietary fat and breast cancer risk. Br J Cancer 68(3): 627–636PubMedGoogle Scholar

Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481–488PubMedCrossRefGoogle Scholar

Boyle P, Zheng T (2001) Environmental features influencing the epidemiology of breast cancer. Breast 10(S 3): 1–8Google Scholar

Braun S, Pantel K, Muller P et al. (2000). Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342(8): 525–533PubMedCrossRefGoogle Scholar

Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349(9064): 1505–1510CrossRefGoogle Scholar

Burkman RT, Tang M-TC, Malone KE et al. (2003) Findings from the National Institute of Child Health and Human Development. Women’s Contraceptive and Reproductive Experiences Study. Fertil Steril 79: 844–851PubMedCrossRefGoogle Scholar

Buzdar AU, Jonat W, Howell A et al. (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83(6): 1142–1152PubMedCrossRefGoogle Scholar

Carmichael J (2001) UKCCCR trial of epirubicin and cyclophosphamide vs epirubicin and taxol in the first line treatment of women with metastatic breast cancer. Proc ASCO 20: 84Google Scholar

Carter CL, Jones DY, Schatzkin A, Brinton LA (1989) A prospective study of reproductive, familial and socioeconomic risk factors for breast cancer using NHANES I data. Public Health Rep 104(1): 45–50PubMedGoogle Scholar

Chan S, Noel D, Pinter T et al. (1999) on behalf of the entire 303 study group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354PubMedGoogle Scholar

Chen AM, Meric-Bernstam F, Hunt KK et al. (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22: 2303–2312PubMedCrossRefGoogle Scholar

Citron ML, Berry DA, Cirrincione C et al. (2003) Randomized trial of dose-dense versus conventionally schedulded and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439PubMedCrossRefGoogle Scholar

Clemons M, Hamilton T, Goss P (2001) Does treatment at the time of locoregional failure of breast cancer alter prognosis? Cancer Treat Rev 27(2): 83–97PubMedCrossRefGoogle Scholar

Coombes RC, Hall E, Snowdon CF, Bliss JM (2004) The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis, SABCS 2004, No 3Google Scholar

Cummings SR, Eckert S, Krueger KA, Grady D et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281(23): 2189–2197PubMedCrossRefGoogle Scholar

Cuzick J (2005) Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23: 1636–1643PubMedCrossRefGoogle Scholar

Cuzick J (1998) Continuation of the International Breast Cancer Intervention Study (IBIS). Eur J Cancer 34(11): 1647–1648PubMedGoogle Scholar

Cuzick J, Powles T, Veronesi U et al. (2003) Overview of the main outcomes in breast cancer prevention trials. Lancet 361: 296–300PubMedCrossRefGoogle Scholar

Dalberg K, Mattsson A, Sandelin K, Rutqvist LE (1998) Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer. Breast Cancer Res Treat 49(1): 69–78PubMedCrossRefGoogle Scholar

Davidson N, O’Neill A, Vukov A, Osborne CK, Martino S, White D, Abeloff MD for ECOG, SWOG, and CALGB (1999) Effect of chemohormonal therapy in premenopausal, node+, receptor+ breast cancer. An Eastern Cooperative Oncology Group Phase III Intergroup trial (E51288, INT-0101). Proc ASCO 18: 67aGoogle Scholar

De Larco JE, Reynolds R, Carlberg K, Engle C, Todaro GJ (1980) Sarcoma growth factor from mouse sarcoma virus-transformed cells. Purification by binding and elution from epidermal growth factor receptor-rich cells. J Biol Chem 255(8): 3685–3690PubMedGoogle Scholar

Dirix L, Piccart M, Lohrisch C et al. (2001) Efficacy of and tolerance to exemestane versus tamoxifen in 1st line hormone therapy of postmenopausal metastatic breast cancer patients: A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc ASCO 20: 114Google Scholar

Dombernowsky P, Smith I, Falkson G et al. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16(2): 453–461PubMedGoogle Scholar

Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348: 1189–1196CrossRefGoogle Scholar

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1998a) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467CrossRefGoogle Scholar

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1998b) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942CrossRefGoogle Scholar

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2000) Ovarian ablation for early breast cancer. Cochrane Database Syst Rev CD000485Google Scholar

Early Breast Cancer Trialists’ Collaborative Group (EBCTC) (2005) Effects of chemotherapy for early breast cancer on recurrence and 15-year survival of the randomized trials. Lancet 365: 1687–1717CrossRefGoogle Scholar

Extra JM, Cognetti F, Maraninchi D et al. (2004) Trastuzumab (Herceptin) plus docetaxel versus docetaxel alone as first-line treatment of Her2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial (Abstr 239). Eur J Cancer 2: 125 (Suppl 3)Google Scholar

5th Main Meeting of the Early Breast Cancer Trialists’ Collaborative Group, Oxford, September 2000Google Scholar

Fisher B (1979) Sounding board. Breast cancer management: alternatives to radical mastectomy. N Engl J Med 301(6): 326–328PubMedCrossRefGoogle Scholar

Fisher B, Slack NH, Bross ID (1969) Cancer of the breast: size of neoplasm and prognosis. Cancer 24(5): 1071–1080PubMedGoogle Scholar

Fisher B, Slack N, Katrych D, Wolmark N (1975) Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140(4): 528–534PubMedGoogle Scholar

Fisher B, Brown A, Mamounas E et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operablebreast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493PubMedGoogle Scholar

Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18): 1371–1388PubMedCrossRefGoogle Scholar

Fisher ER, Wang J, Bryant J et al. (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95: 681–695PubMedCrossRefGoogle Scholar

Ford D, Easton DF, Stratton M et al. (1999) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62(3): 676–689CrossRefGoogle Scholar

Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomisid trials involving 31 510 women. J Clin Oncol 16: 3439–3460PubMedGoogle Scholar

Gerber B, Semrau M et al. (2004) Stellenwert der Strahlentherapie in der Primärbehandlung des Mammakarzinoms. Dtsch Ärztebl 101: 2289–2298Google Scholar

Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7(1): 36–44PubMedGoogle Scholar

Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. 7th International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19(18): 3817–3827PubMedGoogle Scholar

Goldhirsch A, Glick JH, Belber RD et al. (2005) Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. J Clin Oncol (in press)Google Scholar

Goldhirsch A, Wood WC, Gelber RD et al. (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21(17): 3357–3365PubMedCrossRefGoogle Scholar

Goss PE, Ingle JN, Martino S et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802PubMedCrossRefGoogle Scholar

Goss PE, Ingle JN, Martino S et al. (2004) Updated analysis of the NCIC CTG MA. 17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc ASCO No 847Google Scholar

Haagensen CD (1986) Diseases of the breast, 3rd edn. Philadelphia: SaundersGoogle Scholar

Halsted W (1894) The results of operations for cure of cancer of the breast performed at John Hopkins Hospital. Johns Hopkins Hosp Bull 4: 497–507Google Scholar

Hamilton A, Hortobagyi G (2005) Chemotherapy: What progress in the last 5 years? J Clin Oncol 23: 1760–1775PubMedCrossRefGoogle Scholar

Hann LE, Kim CM, Gonen M et al. (2003) Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. J Ultrasound Med 22: 1173–1179PubMedGoogle Scholar

Harris JR, Hellman S (1996) Natural history of breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the breast. Philadelphia: Lippincott-RavenGoogle Scholar

Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340(2): 77–84PubMedCrossRefGoogle Scholar

Henderson IC, Berry DA, Demetri GD et al. for CALGB, ECOG, SWOG, and NCCTG (1998) Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node positive breast cancer. Proc ASCO 17: 390AGoogle Scholar

Henderson IC, Berry DA, Demetri GD et al. (2003) Improved outcomes from adding sequential paclitaxel but not from the escalation of doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6): 976–83PubMedCrossRefGoogle Scholar

Hillner BE, Ingle JN, Chlebowski RT et al. (2003) ASCO 2003 update on the role of biphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042–4057PubMedCrossRefGoogle Scholar

Honkoop AH, Wagstaff J, Pinedo HM (1998) Management of stage III breast cancer. Oncology 55: 218–227PubMedCrossRefGoogle Scholar

Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339: 974–984PubMedCrossRefGoogle Scholar

Houghton J, Baum M, Rutqvist L, Nordensjkold B, Nicolucci A, Sawyer W (2001) The ZIPP trial of adjuvant zoladex in premenopausal patients with early breast cancer: An update at five years. Proc ASCO 19: 93aGoogle Scholar

Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW (1999) Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220–1226PubMedCrossRefGoogle Scholar

Howell A (2002) Fulvestrant, formerly ICI 182, 780 is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403PubMedCrossRefGoogle Scholar

Howell T on behalf of the ATAC Trialist’ Group (2004) The ATAC trial in postmenopausal women with early breast cancer — updated efficacy results based on a median follow-up of 5 years. SABCS No 1Google Scholar

Howell A, Cuzick J, Baum M et al. (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years adjuvant treatment for breast cancer, Lancet 365(9453): 60–62PubMedCrossRefGoogle Scholar

IBIS Investigators (eds) (2002) First results from the international breast cancer intervention study (ibis-i): a randomised prevention trial. IBIS Trial Centre, Cancer Research UK, London. Lancet 360: 817–824Google Scholar

Jackesz (1999) ASCOGoogle Scholar

Jakesz R, Hausmaninger H, Samonigg H (1999) Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four year results of ABCSG trial 5. Proc ASCO 18: 67aGoogle Scholar

Jakesz R, Hausmaninger H, Kubista E et al. (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormoneresponsive breast cancer — Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20: 4621–4627PubMedCrossRefGoogle Scholar

Jakesz R, Kaufmann M, Gnant M et al. on behalf of the ABCSG and GABG (2004) Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. SABCS No 2Google Scholar

Jemal A, Clegg LX, Ward E et al. (2004) Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101: 3–27PubMedCrossRefGoogle Scholar

Jernstrom H, Lerman C, Ghadirian P et al. (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354(9193):1846–1850PubMedCrossRefGoogle Scholar

Jonat W, Kaufmann M, Sauerbrei W et al. (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20: 4628–4635PubMedCrossRefGoogle Scholar

Jones S, Erban J, Overmoyer B, Budd GT, Hutchins XL, Lower E, Laufman L, Sundaram S, Urba W, Olsen S, Meyers ML, Ravdin PM (2003) Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 82(Suppl 1) (Abstr 10)Google Scholar

Jordan VC (2001) Oestrogen receptors, growth factors and the control of breast cancer. The Breast 10(S3): 27–35Google Scholar

Kauff ND, Satagopan JM, Robson ME et al. (2002) Risk reducing salpingo-oophorectomy in women with a BRCA-1 or BRCA-2 mutation. N Engl J Med 34: 1609–1615CrossRefGoogle Scholar

Kaufmann M (2005) Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 14(Suppl 1): S29Google Scholar

Kaufmann M, Loibl S (2005) Basiswissen Praxis. Mammakarzinom. 100 Fragen — 100 Antworten. Medizin und Wissen. München: Urban & VogelGoogle Scholar

Kaufmann M, von Minckwitz G (1996) Das primäre Mammakarzinom. Vorschläge und aktuelle Äspekte zur adjuvanten systemischen Therapie. Dtsch Arztebl 93: A-755–A-758Google Scholar

Kaufmann M, von Minckwitz G (1999) Systemische Therapie metastasierter Mammakarzinome. Dtsch Ärztebl 96: A-2509–A-2512Google Scholar

Kaufmann M, von Minckwitz G (2001) Bericht über die NIH Consensus Development Conference zur adjuvanten Therapie von Mammakarzinomen. Onkol 24: 190–192CrossRefGoogle Scholar

Kaufmann M, Jonat W, von Minckwitz G (2005) Aktuelle Empfehlungen zur Therapie primärer Mammakarzinome. Dtsch Ärztebl (in press)Google Scholar

Kaufmann M, Jonat W, Kleeberg U et al. (1989) Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol 7: 1113–1119PubMedGoogle Scholar

Kaufmann M, Henderson IC, Enghofer E (1989) Consensus development in cancer therapy 1. Therapeutic management of metastatic breast cancer. Berlin New York: de GruyterGoogle Scholar

Kaufmann M, Jonat W, Abel U (1993) Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in woman with node-positive breast cancer. J Clin Oncol 11: 454–460PubMedGoogle Scholar

Kaufmann M, Maass H, Alt D, Schmidt CR (1996) Ein Jahrhundert endokrine Therapie des Mammakarzinoms. Berlin Heidelberg New York: SpringerGoogle Scholar

Kaufmann M, Bajetta E, Dorix LY et al. (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 18: 1399–1411PubMedGoogle Scholar

Kaufmann M, von Minckwitz G for the German Adjuvant Breast Cancer Study Group (GABG) (2001a) The emerging role of hormonal ablation as adjuvant therapy in node+ and node-pre-/perimenopausal patients. Breast 10(Suppl 3): 123–129Google Scholar

Kaufmann M, Jonat W, von Minckwitz G (2001b) Aktuelle Empfehlungen zur Therapie primärer Mammakarzinome. Dtsch Ärztebl 98(33): A2121–A2123Google Scholar

Kaufmann M, Loibl S, Solbach C (2002) Ärztlicher Ratgeber Brustkrebs. Baierbrunn: Wort und Bild-VerlagGoogle Scholar

Kaufmann M, Jonat W, Blamey R et al. (2003) Survival analyses from the ZEBRA study (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39: 1711–1717PubMedCrossRefGoogle Scholar

Kaufmann M, von Minckwitz G, Smith R et al. (2003) International expert panel on the use of primary (preoperative) systematic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21(13): 2600–2608PubMedCrossRefGoogle Scholar

Kaufmann M, Jakesz R, Gnant M et al. (2005) Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95. Breast 14(Suppl 1): P81Google Scholar

Kaufmann M, Jonat W, Eiermann W et al. (2005) Systemische Therapie operabler Mammakarzinome. 9. Int Konf St. Gallen. Zentralbl Gynäkol 4 (im Druck)Google Scholar

Key TJ, Allen NE (2001) Nutrition and breast cancer. Breast 10(S 3): 9–13Google Scholar

Khoury-Collado F, Bombard A (2004) Hereditary breast and ovarian cancer: What the primary care physician should know. Obstet Gynecol Scand 59: 537–542CrossRefGoogle Scholar

Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined Hormone Agents Trialists’ Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19(2): 343–353PubMedGoogle Scholar

Konecny G, Thomssen C, Pegram M et al. (2001) Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Proc ASCO 20: 88Google Scholar

Kretzler A, Molls M (1997) Grundlagen der Radiotherapiebehandlung ossärer Metastasen. In: Böttcher HD et al. (Hrsg) Klinik der Skelettmetastasen — Grundlagen, Diagnostik und Therapie. München: ZuckschwerdtGoogle Scholar

Levine MN, Bramwell VH, Pritchard KL et al. (1998) Randomized trial of intensive cyclophoshamide, epirubicin and fluorouracil chemotherapy compared with cyclophoshamide, methothrexat and fluorouracil in premenopausal women wiht node-positive breast cancer. J Clin Oncol 16: 2651–2658PubMedGoogle Scholar

Li N, Bellow J, Winer E (2004) CNS metastases in breast cancer. J Clin Oncol 22: 3608–3617CrossRefGoogle Scholar

Lohrisch C, di Leo A, Piccart M (2001) Optimal adjuvant cytotoxic therapy for breast cancer. ASCO Educational Book: 61–70Google Scholar

Lück HJ, Thomssen C, Untch M et al. (2000) Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the ago breast cancer group. Proc ASCO 19: 280Google Scholar

Mamounas EP (2000) Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary nodes. NIH Consensus Development Conference on adjuvant therapy for breast cancer. BethesdaGoogle Scholar

Mamounas EP, Bryant J, Lembersky BC et al. (2003) Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc ASCO No 12Google Scholar

Martin M, Pienkowski T, Mackey J et al. (2003) TAC improves disease free survival and overall survival over FAC in node-positive early breast cancer patients, BCIRG 001: 55 months follow-up. SABCS No 43Google Scholar

Martino S, Canley J, Barett-Connor E et al. (2004) Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: resulsts from the Continuing Outcomes Relevant to Evista (CORE) trial. Proc Am Soc Clin Oncol 22: 14SGoogle Scholar

Mauriac L (2003) Fulvestrant (Faslodex TM) versus anastrozole for the treatment of advanced breast cancer in a subgroup of postmenopausal women with visceral an non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 39: 1228–1233PubMedCrossRefGoogle Scholar

McTiernann A, Kooperberg C, White E et al. (2003) Recreational physical activity and the risk of breast cancer in postmenopausal women: the women’s health initiative cohort study. JAMA 290: 1331–1336CrossRefGoogle Scholar

Möbus V, Untch M, Du Bois A et al. (2004) Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (? 4 + LN). First results of an AGO-trial. Proc ASCO 22Google Scholar

Muller A, Homey B, Soto H et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824): 50–56PubMedCrossRefGoogle Scholar

Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22): 3758–3767PubMedGoogle Scholar

Nabholtz JM, Falkson G, Campos D et al. (1999) on behalf of the international TAX306 study group. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc ASCO 18: 485Google Scholar

Nabholtz JA, Paterson A, Dirix L et al. (2001) A Phase III randomized trial comparing docetaxel, doxorubicin and cyclophosphamide to FAC as first line chemotherapy for patients with metastatic breast cancer. Proc ASCO 20: 83Google Scholar

National Cancer Institute. U. S. Institutes of Health. www.cancer.govGoogle Scholar

National Institutes of Health Consensus Development Statement (1997) Breast Cancer Screening for Women ages 40–49Google Scholar

Oberhoff C, Kieback DG, Wurstlein R et al. (2001) Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24(3): 256–260PubMedCrossRefGoogle Scholar

Olsen AH, Njor SH, Vejborg I et al. (2005) Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ 330: 220PubMedCrossRefGoogle Scholar

Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23: 1616–1622PubMedCrossRefGoogle Scholar

O’shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823PubMedCrossRefGoogle Scholar

Osin P, Gusterson BA, Philp E, Waller J, Bartek J, Peto J, Crook T (1998) Predicted anti-oestrogen restistance in BRCA-associated familial breast cancers. Eur j Cancer 34(11): 1683–1686PubMedCrossRefGoogle Scholar

Paget S (1889) The distribution of secondary growth in cancer of the breast. Lancet I: 571–573CrossRefGoogle Scholar

Paridaens R, Therasse P, Dirix L et al. (2004) First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) — A randomized phase III trial of the EORTC Breast Group. Proc ASCO 22: 14S (Abstr 515)Google Scholar

Pegram MD, Pietras R, Bajamonde A et al. (2005) Targeted therapy: wave of the future. J Clin Oncol 23: 1776–1781PubMedCrossRefGoogle Scholar

Peto R (2004) Meta-analysis on local therapy, P5. Plenary lecture at 2004 San Antonio Breast Cancer SymposiumGoogle Scholar

Peto R, Boreham J, Clarke M et al. (2000) UK and USA breast cancer deaths down 25 % in year 2000 at ages 20–69 years. Lancet 335: 1822CrossRefGoogle Scholar

Pienkowski T, Fumeleau P, Eiermann W et al. (2001) Taxotere, cisplatin and herceptin (TCH) in first line Her positive metastatic breast cancer patients. A phase II pilot study by the Breast Cancer International Research Group. Proc ASCO 20: 2030Google Scholar

Pierce LJ (2005) The use of radiotherapy after mastectomy: A review of the literature. J Clin Oncol 23: 1706–1717PubMedCrossRefGoogle Scholar

Poirot C, Vacher-Lavenu MC, Helardot P et al. (2002) Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod 17: 1447–1452PubMedCrossRefGoogle Scholar

Polednak AP (2003) Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Ann Surg 237: 163–167PubMedCrossRefGoogle Scholar

Possinger K, Kaufmann M, Coleman R et al. (1999) Phase II study of gemcitabine as fist line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10: 155–162PubMedGoogle Scholar

Powles T, Eeles R, Ashley S, Easton D, Chang j, Dowsett M, Tidy A, Viggers J, Davey j (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lanced 352(9122): 98–101CrossRefGoogle Scholar

Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocrine-related Cancer 8: 11–31PubMedCrossRefGoogle Scholar

Rebbeck TR, levin AM, Eisen A et al. (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91(17): 1475–1459PubMedCrossRefGoogle Scholar

Reid IR, Brown JP, Burckhardt P et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653–661PubMedCrossRefGoogle Scholar

Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791–808PubMedCrossRefGoogle Scholar

Robert Koch-Institut (Hrsg) (2004) Krebs in Deutschland. Häufigkeiten und Trends, 4. Aufl. RKI, BerlinGoogle Scholar

Robert Koch-Institut Evaluation of cancer incidence in germany (2000). www.rki.de/krebs/krebs.htmlGoogle Scholar

Robertson JF (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98: 229–283PubMedCrossRefGoogle Scholar

Roché H, Fumoleau P, Spielmann M, T et al. (2004) Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node-positive breast cancer. SABCS 2004 No 27Google Scholar

Rozan S, Vincent-Salomon A, Zafrani B et al. (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27–33PubMedCrossRefGoogle Scholar

Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Ferno M, Parwaresch R (1999) Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathology 187: 207–216CrossRefGoogle Scholar

San Antonio Breast Cancer Meeting 2000Google Scholar

Scharl A, Costa SD, von Minckwitz G, Kaufmann M (1998) Neuere Entwicklungen und operative Möglichkeiten bei der Behandlung von Brustkrebs. Forschung Frankfurt 4: 54–66Google Scholar

Schneider BP, Miller (2005) Angiogenesis of breast cancer. J Clin Oncol 23: 1782–1790PubMedCrossRefGoogle Scholar

Seidmann AD, Berry D, Cirrincione C et al. (2004) CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for Her-2-positiv MBC and randomized for T in Her-2-normal MBC. Proc ASCO 22, 14S (Abstr 512)Google Scholar

Sinn HP, Anton HW, Magener A, von Fournier D, Bastert G, Otto HF (1998) Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. Eur J Cancer 34(5): 646–653PubMedCrossRefGoogle Scholar

Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against Her-2 for metastatic breast cancer that overexpresses Her-2. N Engl J Med 344(11): 783–792PubMedCrossRefGoogle Scholar

Smart CR, Hendrick RE, Rutledge III JH, Smith RA (1997) Benefit of mammography screening in women ages 40–49; current evidences from randomized controlled trials. In: NIH Consensus Development Conference. Breast cancer screening for women ages 40–49. Abstr book: 83–90Google Scholar

Smith RA, Duffy SW et al. (2004) The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 42: 793–806PubMedCrossRefGoogle Scholar

Strasser-Weippl K, Goss PE (2005) Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 23: 1751–1759PubMedCrossRefGoogle Scholar

Thiersch C (1865) Der Epithelialkrebs namentlich der Haut. Leipzig: EngelmannGoogle Scholar

Thor AD, Berry DA, Budman DR et al. (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346–1360PubMedCrossRefGoogle Scholar

Thor AD, Liu S, Moore DH 2nd, Edgerton SM (1999) Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17: 470–477PubMedGoogle Scholar

Thuerlimann B on behalf of the BIG 1-98 Collaborative Group (2005) Letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women receptor-positiv breast cancer. BIG 1-98: A prospective randomised double-blind phase III study. Breast 14(Suppl 1): S4Google Scholar

Terry MB, Gammon Marilie D, Zhang FF et al. (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291: 2433–2440PubMedCrossRefGoogle Scholar

Tetu B, Brisson J, Plante V, Bernard P (1998) p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 11: 823–830)PubMedGoogle Scholar

Vahabi M (2003) Breast cancer screening methods: a review of the evidence. Health Care Women Int 24: 773–793PubMedCrossRefGoogle Scholar

Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Cancer 41: 1170–1178PubMedGoogle Scholar

van’t Veer LJ, Paik S, Hayes DF (2005) Gene expression profiiling of breast cancer: A new tumor marker. J Clin Oncol 23: 1631–1635CrossRefGoogle Scholar

Varmus HE, Vogt PK, Bishop JM (1973) Integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts. Proc Natl Acad Sci USA 70(11): 3067–3071PubMedCrossRefGoogle Scholar

Vergote I (2003) Postmenopausal women who progress on fulvestrant („Faslodex“) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 79: 207–11PubMedCrossRefGoogle Scholar

Veronesi U, Rilke F, Luini A et al. (1987) Distribution of axillary lymph node metastases by level of invasion: An analysis of 539 cases. Cancer 59: 682–687PubMedGoogle Scholar

Veronesi U, Saccozzi R, Del Vecchio M et al. (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 305(1): 6–11PubMedCrossRefGoogle Scholar

Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352(9122): 93–97PubMedCrossRefGoogle Scholar

Vogel C, Cobleigh M, Tripathy D, Mass R, Murphy M, Stewart SJ (2001) Superior outcomes with herceptin (trastuzumab) in fluorescence in situ hybridisation — selected patients. Proc ASCO 20: 86Google Scholar

von Minckwitz G, Kaufmann M (1997) Mammographie-Screening für Frauen zwischen 40 und 49. Dtsch Ärztebl 94 A: 1436–1438Google Scholar

von Minckwitz G, Costa SD, Kaufmann M (1998a) Hochdosis Chemotherapie beim Mammakarzinom. Schlusswort. Dtsch Ärztebl 95: B-674–B-677Google Scholar

von Minckwitz G, Costa SD, Kaufmann M (1998b) Allgemeine Chemotherapie In: Wulf KH, Schmidt-Mathiesen H (Hrsg) Klinik der Frauenheilkunde und Geburtshilfe. Allgemeine gynäkologische Onkologie, 4. Aufl. München: Urban & SchwarzenbergGoogle Scholar

von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, Kaufmann M (1999) Maximized reduction of primary breast tumor size using preoperative chemotherapy with adriamycin and docetaxel. J Clin Oncol 17: 1999–2005Google Scholar

von Minckwitz G, Sinn HP, Raab G, Blohmer JU, Graf E, Kaufmann M (2000) Evaluation of predictive factors in a randomized trial of preoperative dose-intensified adriamycin-docetaxel +/-tamoxifen in primary operable breast cancer. Breast Cancer Res Treat 64(1): 303 (Abstr)Google Scholar

von Minckwitz G, Jonat W, Fasching P et al. (2005) Gefitinib in taxane-pretreated metastatic breast cancer. A multicenter phase II study on gefitinib in taxane-and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89: 165–172CrossRefGoogle Scholar

Voogd AC, Nielsen M, Peterse JL et al. (2001) Danish Breast Cancer Cooperative Group. Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19(6): 1688–1697PubMedGoogle Scholar

Waldeyer W (1872) Die Entwicklung der Carcinome. Virchows Arch Pathol Anat 55: 67–159CrossRefGoogle Scholar

Wang J, Costantino JR, Tan-Chiu E et al. (2004) Lower-category benign breast disease and the risk of invasive breast cancer. Obstetr Gynecol Surv 59(8): 590–592CrossRefGoogle Scholar

Winer EP, Hudis C, Burstein HJ et al. (2004) American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin OncolGoogle Scholar

Wittekind C, Meyer HJ, Bootz F (2002) TNM Klassifikation maligner Tumoren, 6. Aufl. (Hrsg UICC) Berlin Heidelberg New York: SpringerGoogle Scholar

Yeh I, Fowble B, Vigione MJ et al. (1991) Pathologic assessment and pathologic prognostic factors in operable breast cancer. In: Fowble B, Goodman RL, Glick JH, Rosato EF (eds) Breast cancer treatment: a comprehensive guide to treatment. Mosby-Yearbook: St. Louis, p 171Google Scholar

Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017–1021PubMedCrossRefGoogle Scholar